APC-APN-306
15 evidence topics · 4 sources
Objective
Long-term safety of AD109 in participants completing a parent phase 3 trial
Exploratory objectives: night-to-night variability by ring oximetry and patient-reported outcomes by mobile application
Location and study date
Registry dates and status, last updated May 2025
| Field | Registry entry |
|---|---|
| Study start (actual) | “2024-07-03” |
| Primary completion (estimated) | “2026-06-30” |
| Last update posted | “2025-05-13” |
Completion of the open-label extension in 2026 per the company
Study design
Phase 3, single-group, open-label continuation protocol
Washout before open-label dosing and serial safety assessments
Safety follow-up for up to an additional year after either phase 3 trial
Eligibility criteria
Completion of a parent phase 3 trial without permanent discontinuation of study drug
Treatment
Open-label fixed-dose combination of aroxybutynin and atomoxetine
Study outcomes
Rationale for using incidence of adverse events as the primary endpoint
Registry primary outcome measures: adverse events, vital sign abnormalities, and concomitant therapy
Safety assessments and exploratory oximetry parameters
Statistical analysis description
Number of participants (Planned and analyzed)
Planned enrollment
| Field | Registry entry |
|---|---|
| Enrollment (estimated) | “1280” |
Description of analysis sets
No evidence found.
Results
Participant disposition
Interim enrollment and uptake of exploratory data collection
Baseline characteristics
No evidence found.
Efficacy results
No evidence found.
Health-related quality of life and patient-reported outcomes
No evidence found.
Safety results
Interim safety conclusion stated without data
Study limitations
Summary
- Design: open-label, single-group continuation study with no comparator; the registered primary outcomes are counts of participants with adverse events, vital sign abnormalities, and concomitant therapy.
- Population: eligibility required completion of a parent phase 3 trial without permanent discontinuation of study drug, so participants who stopped study drug in the parent trials were not eligible.
- Status: the registry record (last updated 2025-05-13) lists an estimated enrollment of 1,280 and an estimated primary completion of 2026-06-30, while the prospectus states the trial was completed in 2026.
- Results: the only results are interim data from a 2025 congress abstract, with 102 participants enrolled (70% of eligible). The abstract states that data collected to date support long-term safety without reporting adverse event data, and no baseline, efficacy, patient-reported outcome, or analysis-set information is available.
- Exploratory ring oximetry and mobile-application PROs were optional; 73 participants (72%) opted in.
- Sponsor: the prospectus states that Syneos provided services to the company in connection with the trial.